peptides protocol FAQ

Injection site reactions (redness, swelling, mild pain) occur more frequently when multiple peptides are administered in the same subcutaneous region within a short timeframe. The issue isn't peptide interaction. It's localized immune activation from repeated needle punctures and depot formation. Solutions: (1) rotate injection sites daily (abdomen, thigh, deltoid if using small volumes), (2) space injections by at least 4 hours even if using different sites, (3) ensure proper reconstitution technique (bacteriostatic water, slow mixing to avoid protein denaturation), (4) reduce injection volume per site by splitting doses if using very high concentrations. If reactions persist, consider switching one peptide to an alternative administration route. Some peptides like Semax Nasal Spray or Selank Nasal Spray bypass subcutaneous injection entirely.

Check the bundle's ingredient list for receptor pathway overlap before combining it with standalone ARA-290. Bundles like FAT Loss Stack or Sleep Stack typically contain compounds targeting metabolic or neurotransmitter pathways (e.g., GLP-1 analogs, GABA modulators) that don't overlap with ARA-290's IRR mechanism. As long as the bundle doesn't contain EPO, high-dose BPC-157, or other compounds that activate JAK2/STAT3 or PI3K/Akt at saturation levels, you can add ARA-290 to the protocol. Administer ARA-290 separately. If the bundle is taken morning and evening, dose ARA-290 mid-afternoon to avoid injection site saturation.

Yes, if your research goal includes inflammation control or tissue repair beyond what GH/IGF-1 alone provides. Growth hormone secretagogues like GHRP-2 or MK-677 stimulate pituitary GH release, which increases IGF-1 and supports anabolic processes. But they don't directly suppress inflammatory cytokines or activate the innate repair receptor. ARA-290 fills that gap. Protocol: continue your existing GH secretagogue regimen, add ARA-290 4mg once daily (morning or evening depending on when you want peak anti-inflammatory coverage). No dose adjustment needed for the GH compound. The pathways don't compete.

Yes, with no direct interaction expected. GLP-1 receptor agonists (semaglutide, tirzepatide) work through incretin signaling to regulate insulin secretion and appetite, which doesn't overlap with Pinealon's neuronal gene expression mechanism. However, GLP-1 agonists are known to cross the blood-brain barrier and exert neuroprotective effects through GLP-1 receptor activation in the hippocampus. This is mechanistically separate from Pinealon but targets a similar outcome (neuroprotection). Combining the two doesn't create receptor competition, but it does mean you're addressing neuroprotection through two independent pathways, which is generally beneficial. No dose adjustment is required for either compound.

Administering them separately reduces synergy. The GH pulse induced by sermorelin peaks 20–40 minutes post-injection and returns to baseline within 90–120 minutes. If GHRP-2 is given hours later, it produces a separate pulse rather than amplifying the sermorelin-induced pulse. For maximal synergy, both peptides must be active simultaneously. Inject them together or within 5–10 minutes of each other.

This combination is viable but requires monitoring for receptor desensitisation. MK-677 provides continuous ghrelin receptor stimulation (24-hour half-life), while sermorelin delivers pulsatile GHRH activation. The result is baseline IGF-1 elevation from MK-677 plus intermittent GH pulses from sermorelin. Some research protocols report diminished response to MK-677 after 8–12 weeks of daily dosing. If baseline IGF-1 begins declining, consider cycling MK-677 (5 days on, 2 days off) or switching to a pulsatile GHRP instead.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) modulates GABA and serotonin pathways through a mechanism distinct from Pinealon's gene expression effects, making the combination mechanistically compatible. Pinealon addresses long-term neuronal resilience, while Selank provides acute anxiolytic and attention-regulating effects. Research protocols typically dose Pinealon 10mg subcutaneously daily and Selank 300–600mcg intranasally 1–2 times daily. The caveat: both peptides have relatively short half-lives (Pinealon approximately 2–3 hours, Selank 20–30 minutes after intranasal administration), so timing matters. Administer Selank 30–60 minutes before cognitively demanding tasks, and Pinealon first thing in the morning to allow gene expression changes to take effect throughout the day.

This is a common three-peptide stack for comprehensive neuroprotection and recovery protocols. The mechanisms are fully complementary: Pinealon modulates gene expression, Semax enhances cholinergic signaling, and BPC-157 promotes systemic tissue repair. The challenge is injection site management and dosing schedule complexity. A typical structure: Pinealon 10mg SC daily (morning), Semax 600mcg IN once daily (morning), BPC-157 500mcg SC twice daily (morning and evening). Rotate subcutaneous injection sites. Abdomen, lateral thigh, upper arm. To prevent lipodystrophy from repeated injections. Store all reconstituted peptides at 2–8°C and use within 28 days. Multi-peptide protocols increase the risk of vial mix-ups, so label each vial clearly with compound name and reconstitution date.

Protein denaturation begins within 2–4 hours at temperatures above 8°C. If a reconstituted vial was left unrefrigerated overnight, the peptide structure is likely compromised. Neither visual inspection nor potency can be reliably assessed at home. Discard the vial and reconstitute a fresh sample. This is why bacteriostatic water and immediate refrigeration after reconstitution are non-negotiable protocol steps.

Use one GHRP per protocol. Not multiple. Stacking sermorelin with both GHRP-2 and ipamorelin simultaneously doesn't amplify GH release beyond what a single GHRP achieves because all GHRPs activate the same GHS-R1a receptor. The limiting factor is pituitary GH secretory capacity, not receptor availability. Adding a second GHRP increases cost and injection volume without producing measurable additional benefit.

Reduce the dose of the metabolic peptide by 30–50% and reassess after one week. The fatigue likely indicates transient ATP insufficiency from compounding energy demand. Metabolic peptides like AOD-9604 or lipolytic fragments increase mitochondrial fatty acid oxidation, which requires functional electron transport chains to convert released fatty acids into ATP. If SS-31 is simultaneously stabilizing those chains during a high-flux period, mitochondria may struggle to meet total cellular energy requirements. Staggering administration by 4–6 hours or reducing one compound's dose allows mitochondria to adapt without overwhelming capacity.

Administer SS-31 in the morning (fasted state preferred) and GH peptides 30–60 minutes before sleep to separate peak mitochondrial activity windows. GH secretagogues increase anabolic ATP demand 6–8 hours post-injection as protein synthesis ramps up. If you dose SS-31 simultaneously, mitochondria experience a transient mismatch between stabilized electron transport (from SS-31) and elevated energy output requirements (from GH signaling). Research teams using this stacking protocol report optimal results when SS-31 is administered at a consistent circadian timepoint (morning) while GH peptides align with natural nocturnal GH pulses.

Choose one mitochondrial-targeted antioxidant and use it consistently rather than combining them. Redundant mechanisms compete for binding sites without additive benefit. Data from the Buck Institute showed that SS-31 + MitoQ co-administration reduced individual compound efficacy by 34% compared to monotherapy, likely because both molecules accumulate at cardiolipin-rich sites and interfere with each other's membrane interaction. If your research goal is cardiolipin stabilization and cristae preservation, SS-31 is the more specific choice; if the goal is matrix ROS scavenging in already-stable mitochondria, MitoQ may be preferable.

The primary risk is reduced Semax bioavailability (40–60% loss) due to hepatic enzyme competition, not a dangerous interaction. Semax will clear rapidly regardless; Amidate sedation will proceed normally. Monitor for excessive sedation; if cognitive enhancement was the goal, that window is lost—re-dose Semax only after Amidate clears (6+ hours post-administration).

No. Run MK-677 during hexarelin's 4–5 day off-cycle, not concurrently. Both compounds saturate GHS-R1a. Overlapping them accelerates desensitisation and blunts hexarelin's superior GH pulse amplitude within 10 days. The productive approach: use hexarelin 5 days on at 100–200 mcg twice daily, then switch to MK-677 at 10–25 mg daily during the 4-day hexarelin washout. This pattern maintains elevated GH and IGF-1 throughout the cycle without compounding receptor load.

You've hit receptor desensitisation. The most common cause: stacking hexarelin with another GHS-R1a agonist (GHRP-2, GHRP-6, or concurrent MK-677) without adequate off-days. Implement an immediate 7-day washout from all ghrelin receptor ligands. Resume hexarelin only with a strict 5 on / 4 off cycle and pair it exclusively with CJC-1295, which acts through GHRH receptors and won't compound the saturation problem. If you were running hexarelin + GHRP-2 together, eliminate GHRP-2 entirely. It adds receptor load without synergy.

The peptide you stacked likely has GABA-ergic or serotonergic sedative properties not accounted for in the protocol design. Cross-check the secondary peptide's mechanism—compounds like Selank or phenibut cause sedation in 20–35% of users when combined with other CNS-active agents. Discontinue the sedative compound; Semax alone does not cause sedation.

Stop hexarelin immediately and allow a 7–10 day washout period before restarting. Three weeks of continuous hexarelin dosing has likely caused significant ghrelin receptor internalisation. Your GH response is diminished even if you're still injecting. The receptor needs time to repopulate at the cell membrane before hexarelin will work effectively again. During washout, you can maintain GH stimulation with CJC-1295 or low-dose ipamorelin, both of which preserve receptor function for hexarelin's return.

Sequence by half-life: shortest first, longest last, with minimum 30-minute intervals between each administration. Example protocol—Semax (intranasal, 0 min) → Dihexa (subcutaneous, +30 min) → Cerebrolysin (IM, +90 min) → MK-677 (oral, evening dose 8+ hours later). Track receptor pathways—avoid stacking two peptides that both modulate the same neurotransmitter system within 4 hours.

Begin with TB-500 and GHK-Cu only. Skip BPC-157 entirely. The angiogenic window (days 0–7) has already closed; adding BPC-157 at week two provides minimal vascular benefit because endothelial proliferation peaks in the first 96 hours post-injury. TB-500 remains effective during the proliferative phase (days 7–21), and GHK-Cu supports collagen maturation throughout remodeling. Researchers starting late consistently report better outcomes focusing resources on the two peptides aligned with current injury biology rather than dosing all three out of phase.